Tuesday, July 4, 2023
This drug developed by AI for lungs disease enters human clinical trials
Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has a new AI-designed drug named INS018-055 that has entered human clinical trials. Insilico Medicine has developed this drug named using its generative AI platform. INS018-055 clinical trials taking place in China could offer an alternative treatment with fewer side effects. Insilico Medicine is also developing two more drugs using AI, a Covid-19 drug in Phase one trial, and a USP1 inhibitor for the treatment of solid tumours that has already received FDA approval. https://ift.tt/wUZB8DE
Subscribe to:
Post Comments (Atom)
A look at the deluge of AI computing power set to come online in the coming years; Epoch AI expects the number of AI chips in use to double every nine months (New York Times)
New York Times : A look at the deluge of AI computing power set to come online in the coming years; Epoch AI expects the number of AI chi...
-
Sohee Kim / Bloomberg : South Korean authorities are investigating a data leak at e-commerce giant Coupang that exposed ~33.7M accounts; ...
-
http://bit.ly/2XqNIDz
No comments:
Post a Comment